藥學相關資料庫的選擇與應用

義大醫療財團法人義大醫院
藥劑部　黃佳真藥師

2012/7/14 (六)

普及率最高的藥物資料庫

MICROMEDEX® 2.0

- 點閱率排行榜

機構所訂購的子資料庫內容



基本藥物資訊查詢

以Dronedarone為例

使用劑量與注意事項?

Dronedarone Hydrochloride [Your search: Dronedarone]

Oral

360° 檢視儀錶板 | 跳轉到 413 其他搜尋結果

MICROMEDEX 藥物綜述資訊

- Adult Dosing
- Pediatric Dosing
- Dose Adjustments
- FDA-Labeled Indications
- Non-FDA Labeled Indications
- Black Box Warning
- Contraindications
- Precautions
- Pregnancy Category
- Breast Feeding
- Drug Interactions (single)
- Adverse Effects - Common
- Adverse Effects - Serious
- US Trade Names
- Class
- Regulatory Status
- Generic Availability
- Mechanism of Action/Pharmacokinetics
- Administration/Monitoring
- How Supplied
- Toxicology - Clinical Effects
- Toxicology - Treatment
- Toxicology - Range of Toxicity
- Clinical Teaching
- References

檢視綜述文件 | 檢視詳細文件

其他資訊

MARTINDALE

- Dronedarone

藥物工具

DRUG SAFETY AND AVAILABILITY

- RISK EVALUATION AND MITIGATION STRATEGIES (REMS)

PRODUCT LOOKUP

- Tox & Drug: Dronedarone Hydrochloride
- Martindale: Dronedarone Hydrochloride

DRUG CONSULTS (3 結果)

- ATRIAL FIBRILLATION - DRUG TREATMENT GUIDELINES
- NEW DRUG APPROVALS - 2009 MICROMEDEX NEWS
- RISK EVALUATION AND MITIGATION STRATEGIES (REMS)

COMPARATIVE EFFICACY (1 結果)

- Amiodarone Hydrochloride

MARTINDALE - 其他資訊 (1 結果)

Dosing & Indications



1. Dronedarone不可與CYP3A4 強效抑制劑併用
2. 使用 dronedarone 前必需停用第一類和第三類抗心律不整藥物
3. 陣發性(paroxysmal) OR 持續性(persistent) AF: 400mg BID

Dosing & Indications

DRONEDARONE

顯示整個文件 | 列

DRUGDEX® 評價 其他來源

DOSING INFORMATION 全部展開 | 全部折疊 | 頁

Adult Dosage

Normal Dosage

Important Note

Dronedarone Hydrochloride

Important Note

) Strong CYP3A4 inhibitors (eg, ketoconazole) and Class I or III antiarrhythmics (eg, amiodarone, flecainide, propafenone, quinidine, disopyramide, dofetilide, sotalol) must be discontinued prior to initiating dronedarone hydrochloride [1].

Dronedarone Hydrochloride

Oral route

Atrial fibrillation, Paroxysmal or Persistent

1) To reduce the risk of hospitalization due to atrial fibrillation (AF) for patients in sinus rhythm who have a history of paroxysmal or persistent atrial fibrillation, the recommended dosage of dronedarone hydrochloride is 400 milligrams orally twice daily with the morning and the evening meal [3].

Dosage in Renal Failure

A) Dronedarone Hydrochloride

1) No dronedarone hydrochloride dosage adjustment is recommended in patients with renal impairment [3]

Monitoring Parameters

Comparative Efficacy / Evaluation With Other Therapies

DRONEDARONE

顯示整個文件 | 列

DRUGDEX® 評價 其他來源

CLINICAL APPLICATIONS 全部展開 | 全部折疊 | 頁

Mechanism of Action / Pharmacology

Therapeutic Uses

Comparative Efficacy / Evaluation With Other Therapies

Amiodarone Hydrochloride

Atrial fibrillation

a) Amiodarone was more effective than dronedarone to prevent the recurrence of atrial fibrillation (AF) but dronedarone may have a better safety profile in the Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Dronedarone Versus Amiodarone for at Least 6 Months for the Maintenance of Sinus Rhythm in Patients with AF (DIONYSUS). Patients (n=504; mean age, 64 +/- 10.7 years) with documented AF for more than 72 hours with an

DIONYSOS Study

唯一一個與 amiodarone 進行直接比較的研究

hypertension (66.9%), while 21.6% had congestive heart failure, and 16.5% had lone AF. Most patients had persistent AF (62.9%), while 21.6% were in their first episode. Patients in the

CLINICAL APPLICATIONS

全部展開 | 全部折疊 | 頁

Mechanism of Action / Pharmacology

Therapeutic Uses

Comparative Efficacy / Evaluation With Other Therapies

Amiodarone Hydrochloride

Atrial fibrillation

?

a) Amiodarone was more effective than dronedarone to prevent the recurrence of atrial fibrillation (AF) but dronedarone may have a better safety profile in the Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Dronedarone Versus Amiodarone for at Least 6 Months for the Maintenance of Sinus Rhythm in Patients with AF (DIONYSUS). Patients (n=504; mean age, 64 +/- 10.7 years) with documented AF for more than 72 hours with an indication for cardioversion and antiarrhythmic treatment, and who were receiving oral anticoagulation, were randomized to receive dronedarone 400 mg orally twice daily (n=249) or amiodarone 600 mg orally daily for 28 days followed by 200 mg orally daily (n=255), for at least 6 months. If conversion to normal sinus rhythm did

1. DIONYSOS Study是唯一一個與 amiodarone 進行直接比較的研究(RCT)、不曾使用過 amiodarone 之持續性心房纖維顫動患者隨機分配至400 mg 每日二次 dronedarone 組與 amiodarone 組 (前28天每日一次 amiodarone 600 mg，之後200 mg 每日一次)，各納入249人與255人，
2. 平均治療期間為7個月，在追蹤12個月減少心房纖維顫動復發方面 amiodarone 優於 dronedarone (42% vs. 63.5%)，成功心律復整 (cardioversion) 後再次復發方面 amiodarone 亦比 dronedarone 少 (24.3% vs. 36.5%)；但 dronedarone 組的提早停藥比例較 amiodarone 少 (10.4% vs. 13.3%)
3. 在 DIONYSOS Study中，amiodarone 在降低心房纖維顫動復發效果優於 dronedarone，dronedarone 在甲狀腺和神經方面安全性較高(但 dronedarone 胃腸副作用則多於 amiodarone)。

DRONEDARONE

DRUGDEX® 評價

其他來源

CLINICAL APPLICATIONS

p=0.0311). The median duration of treatment with study drug wa
months). After 12 months of treatment, the composite primary e
(recurrence of AF or premature drug discontinuation due to lack
(premature drug discontinuation due to intolerance) was significa
arm (75.1%) versus the amiodarone arm (58.8%; hazard ratio (H

REFERENCES

[42] Le Heuzey JY, De Ferrari GM, Radzik D, et al: A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol 2010; 21(6):597-605.
PubMed Abstract: http://www.ncbi.nlm.nih.gov/...
PubMed Article: http://www.ncbi.nlm.nih.gov/...

可連結文章全文

MICROMEDEX® 2.0 | 移動

工具: 藥物相互作用 | Trissel's™2 IV 相容性 | 藥物鑒定 | Tox 和藥物產品查找 | 藥物比較 | 計算器

Drug Comparison Results 修改比較

查詢兩種藥物的完整比較

在欄中顯示 1: Amiodarone HCl

在欄中顯示 2: Dronedarone Hydrochloride

更新

跳轉到： 頁首 | Dosing & Indications | Black Box Warning | Contraindications/Warnings | Drug Interactions (single) | Adverse Effects | Name Info | Mechanism of Action/Pharmacokinetics | Administration/Monitoring | How Supplied | Toxicology | Clinical Teaching | References

Amiodarone Hydrochloride
[Amiodarone HCl]

檢視 DRUGDEX 中的詳細資訊

Dosing & Indications

Adult Dosing

檢視 DRUGDEX 中的詳細資訊

- Advanced cardiac life support: 300 mg IV/INTRAOSSEOUSLY by rapid infusion; a single-dose of 150 mg IV/INTRAOSSEOUSLY may be repeated [2]
- Supraventricular arrhythmia: initial, 600 to 1200 mg ORALLY daily for 1 to 2 wks, tapered to 400 to 600 mg ORALLY daily for 1 to 3 wks, tapered to the lowest possible maintenance dose
- Supraventricular arrhythmia: maintenance, 200 mg ORALLY daily
- Supraventricular arrhythmia: IV/ORAL regimen; 300 mg IV for 1 hr, then 20 mg/kg for 24 hrs, then 600 mg ORALLY daily for 1 wk, then 400 mg ORALLY daily

Dronedarone Hydrochloride

檢視 DRUGDEX 中的詳細資訊

Dosing & Indications

Adult Dosing

檢視 DRUGDEX 中的詳細資訊

- strong CYP3A4 inhibitors (eg, ketoconazole) and Class I or III antiarrhythmics (eg, amiodarone, flecainide, propafenone, quinidine, disopyramide, dofetilide, sotalol) must be discontinued prior to initiating dronedarone hydrochloride [1]
- Atrial fibrillation, Paroxysmal or Persistent: 400 mg ORALLY twice daily with morning and evening meals [1]


MICROMEDEX® 2.0 | 移動
我的訂閱 | MICROMEDEX 閘道 | 登出 | 說明
工具: 藥物 相互作用 | Trissel's™2 IV 相容性 | 藥物 鑒定 | Tox 和藥物 產品查找 | 藥物 比較 | 計算器 | CareNotes®
Dronedarone
SEARCH
範例搜尋
可用途徑
Dronedarone Hydrochloride
Dronedarone Hydrochlori
Oral
360° 檢視儀錶板 | 跳轉到 413 其他搜尋結果
MICROMEDEX 藥物綜述資訊
Adult Dosing
Pediatric Dosing
Dose Adjustments
FDA-Labeled Indications
Non-FDA Labeled Indications
Black Box Warning
Contraindications
Precautions
Pregnancy Category
Breast Feeding
Drug Interactions (single)
Adverse Effects - Common
Adverse Effects - Serious
US Trade Names
Class
Regulatory Status
Generic Availability
Mechanism of Action/Pharmacokinetics
Administration/Monitoring
How Supplied
Toxicology - Clinical Effects
Toxicology - Treatment
Toxicology - Range of Toxicity
Clinical Teaching
References
檢視綜述文件 | 檢視詳細文件
其他資訊
MARTINDALE
Dronedarone
藥物工具
風險評估與風險管理
（Risk Evaluation and Mitigation Strategy; REMS）
安全性監測
DRUG SAFETY AND AVAILABILITY
RISK EVALUATION AND MITIGATION STRATEGIES (REMS)
PRODUCT LOOKUP
Tox & Drug: Dronedarone Hydrochloride
Martindale: Dronedarone Hydrochloride
DRUG CONSULTS (3 結果)
ATRIAL FIBRILLATION - DRUG TREATMENT GUIDELINES
NEW DRUG APPROVALS - 2009 MICROMEDEX NEWS
RISK EVALUATION AND MITIGATION STRATEGIES (REMS)
COMPARATIVE EFFICACY (1 結果)
Amiodarone Hydrochloride
MARTINDALE - 其他資訊 (1 結果)

RISK EVALUATION AND MITIGATION STRATEGIES (REMS)

藥物諮詢

RESPONSE

提醒醫師處方前要再次評估利益與風險

The Food and Drug Administration Amendments Act of 2007 (FDAAA) gave FDA the authority to require Risk Evaluation and Mitigation Strategies (REMS) from manufacturers to ensure that the benefits of a drug or biological product outweigh its risks. A REMS may contain:

- A timetable for submission of assessments at 18 months, 3 and 7 years after the date of REMS approval is required.
- Any or all of the Additional Potential Elements:
  - Medication guide
  - Patient package insert that may reduce a serious risk of the drug
  - Communication plan targeted to health care providers

病人用藥須知

降低嚴重風險

教育宣導計畫

- Elements to ensure safe use (ETASU) may be required when the above Additional Potential Elements are not sufficient to reduce the serious risks associate with the drug. The ETASU may include:
  - Certification of prescribers
  - Certification of dispensers
  - Dispensing limited to certain healthcare settings, such as a hospital
  - Dispensing to patients with evidence of safe use, such as laboratory test results
  - Specific patient monitoring requirements
  - Patient registry enrollment

確保安全使用要件

- Implementation system may be required to monitor and evaluate the implementation of the REMS ETASU and to improve the implementation of these elements.

執行系統-追蹤執行成效

Distribution Requirements of Providing Medication Guides

- Inpatient

RISK EVALUATION AND MITIGATION STRATEGIES (REMS)

藥物諮詢

- Inpatient
  - Patient or patient's agent re
  - Drug is subject to an ETASU
- Outpatient when a healthcare pr ment, outpatient
  - Patient or patient's agent re
  - At time of first dispensing
  - When Medication Guide cor
  - Drug is subject to an ETASU
- Outpatient when dispensed dire ples)
  - Patient or patient's agent re
  - Each time the drug is dispe

[1]

- A list of drugs with the FDA app
  - http://www.fda.gov/Drugs/Dr
- A list of Medication Guides is a
  - http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm

參考：

1. U.S. Food and Drug Administration (FDA): Guidance Medication Guides — Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS). U.S. Food and Drug Administration (FDA). Silver Spring, MD. 2011. Available from URL: http://www.fda.go... . As accessed 2011-12-12.

列印 關閉

Reference

1. U.S. Food and Drug Administration (FDA): Guidance Medication Guides — Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies

FDA於2011/12/19發佈安全警訊

✱ 資料來源: http://www.fda.gov/Safety/MedWatch/SafeInformation

Multaq (dronedarone): Drug Safety Communication - Increased Risk of Death or Serious Cardiovascular Events

[Updated 12/19/2011]

FDA 完成一項 Multaq (droneodarone)安全性審查。這項審查說明 Multaq 會增加嚴重心血管疾病的風險，有永久性心房顫動(permanent atrial fibrillation)患者使用 Multaq 甚至會增加死亡的風險。這項審查引用的文獻來自於兩個臨床試驗：PALLAS 和 ATHENA。針對 Multaq 增加心血管疾病的風險，FDA 提供新的建議；Multaq 的仿單也修訂了使用建議：

- 有永久性心房顫動(permanent atrial fibrillation)的患者不應使用 Multaq，因為 Multaq 會增加這類患者的心血管疾病的死亡率，和中風、心衰竭的發生率。
- 使用 Multaq 時，至少每三個月使用心電圖監測心律。若有心房顫動發生，應立即停藥；若臨床需要，應治療患者的心律不整。
- Multaq 用於降低非永久性心房顫動(non-permanent AF, paroxysmal or persistent AF)的患者的住院率。
- 患者使用 Multaq 時，應接受適當的抗血栓治療。

食品藥物管理局說明Dronedarone成分藥品之用藥安全資訊

歐洲醫藥管理局（EMA）近日發布含 dronedarone成分藥品之用藥安全資訊，根據臨床試驗（PALLAS study）研究及2011年該藥品之總體性臨床效益與風險評估報告，顯示使用含該成分藥品可能導致嚴重肝臟傷害及嚴重心臟血管副作用，同時亦可能造成肺部傷害之風險，因此重新規範使用該藥品，同時將持續追蹤該藥品之安全性。

經查，衛生署於99年 6月核准含 dronedarone成分藥品，中文品名為「脈泰克膜衣錠」，英文品名為「Multaq」，作為治療心律不整之用途。該藥品許可證持有廠商，已向衛生署申請仿單更新，最新版之仿單中已加刊相關警語、注意事項，並要求該藥品僅侷限用於病人有陣發性或持續性心房纖維顫動(AF)，且目前處於竇性節律（sinus rhythm）狀態，並需經專科醫師評估無更適當之抗心律不整藥品可供選擇情況下，始可使用。Dronedarone不可用於永久性心房纖維顫動、心臟衰竭、已有肝或肺傷害且已接受Aminodarone或另一種抗心律不整藥品之病人。服用該藥品之病人應定期監視心律及肺、肝功能；初期治療之數週，尤其應密切監視病人之肝功能。衛生署食品藥物管理局提醒正在使用該藥品之病患，勿擅自停藥，若有任何疑慮或不適，應立即回診詢問主治醫師。

食品藥物管理局已建立藥物安全資訊主動監控機制，除有藥物不良反應通報系統之外，對於安全有關訊息，隨時進行瞭解，以保障民眾之用藥安全，[redacted]藥品導致不良反應發生時，請立即通報給衛生署所建[redacted]反應通報專線02-2396-0100，網站：http://adr.doh.gov.tw。

應持續追蹤該藥品之安全性!!

✱ 資料來源：行政院衛生署食品藥管理局 http://www.doh.gov.tw

上市後藥品風險控制

- 採取措施



- 修改仿單、加強藥袋標示
  (例：Bisphosphonates)
- 限制使用 (例如Aliskerin)
- 執行風險管理計畫 (100年新增)
  (例：Pioglitazone, TNA-alpha Blocker)
- 下市 (例：propoxyphene)

行政院衛生署食品藥管理局於2012/1/3 (二) 發佈安全警訊

aliskiren（Rasilez®）之用藥資訊 (發布日期2012-01-03)

歐洲醫藥管理局(EMA)於最近發布新聞指出，治療高血壓藥品aliskiren（藥品名稱Rasilez®）之藥品許可證持有廠商決定終止一項「aliskiren成分藥品新適應症之臨床試驗」，該新適應症之臨床試驗嘗試加入aliskiren於已服用血管收縮素轉化酶抑制劑(ACEI)或血管收縮素受體阻斷劑(ARB)的第二型糖尿病患者，且同時併有腎功能不全或有重大心血管疾病病史之高危險群病人，評估是否可以降低心血管疾病與腎臟疾病的發生率及致死率。其初步結果顯示該項臨床試驗無法提高臨床效益，卻可能會增加非致死性中風、高血鉀、低血壓、腎臟併發症等風險，因此該藥廠決定終止此「新適應症之臨床試驗」。

食品藥物管理局為保障民眾用藥安全，已同步停止國內參與該項新適應症之臨床試驗計畫，並請藥廠儘速提供該臨床試驗計畫報告及相關安全資訊，食品藥物管理局將儘速評估其整體風險與臨床效益。

衛生署自97年9月10日核准含aliskiren成分藥品許可證，目前含該成分藥品許可證共6張，核可之適應症為「治療高血壓」，均為安全監視期之藥品，藥商必須定期提報國內、外定期安全性報告至食品藥物管理局，以利隨時了解其臨床使用情形。經查，全國藥物不良反應通報資料，目前僅有1件非嚴重不良反應通報案例。在衛生署未有進一步評估結果之前，食品藥物管理局建議醫師宜立即檢視正在使用aliskiren的糖尿病患者，如果同時併用血管收縮素轉化酶抑制劑或血管收縮素受體阻斷劑，宜停用aliskiren，並監視病人不良反應情形。服用該成分藥品之糖尿病患者，不可擅自停藥，應回診開立處方之主治醫師。

食品藥物管理局已建立藥物安全資訊主動監控機制，除有藥物不良反應通報系統之外，對於安全有關訊息，隨時進行瞭解，以保障民眾之用藥安全，提醒醫療人員或病患懷疑因為使用（服用）藥品導致不良反應發生時，請立即通報給衛生署所建置之全國藥物不良反應通報中心，藥物不良反應通報專線02-2396-0100，網站：http://adr.doh.gov.tw。

*資料來源: 行政院衛生署食品藥管理局 ***http://goo.gl/gYCM0***

藥物資訊查詢

_Dronedarone藥品使用評估

何處找資料?

- 背景問題 (background question)
  - Dose, indication, monitor, ...

MICROMEDEX® 2.0

- 前景問題 (foreground question)
  - 目前是否有相似的研究?
  - 療效/風險/效益

PubMed

Key關鍵字→ dronedarone→ 349篇



Dronedarone藥品使用評估

"Drug Utilization Evaluation" OR "Drug Utilization Review"

Evaluation of Dronedarone Use in the US Patient Population Between 2009 and 2010: A Descriptive Study Using a Claims Database

Shujun Gao, MD, MPH, PhD[1]; Juhaeri Juhaeri, PhD[1]; Heather A. Schiappacasse, PharmD, MBA[2]; Andrew T. Koren, MD[3]; and Wanju S. Dai, MD[1]

[1]Global Pharmacovigilance and Epidemiology, Sanofi, Bridgewater, New Jersey; [2]US Risk Identification, Surveillance and Communication, Sanofi, Bridgewater, New Jersey; and [3]US Medical Affairs, Sanofi, Bridgewater, New Jersey

ABSTRACT

Backgrou
was unknow
ance with the
lowing its a
Food and D
tion and mit
States.

Objective: This study was designed to evaluate the dronedarone prescribers' adherence to PI regarding the following contraindications: (1) patients with heart failure (HF) with a recent decompensation requiring hospitalization or referral to a specialist, (2) concomitant use of potent CYP3A4 inhibitors, and (3) concomitant use of QT-prolonging drugs.

假如只鍵入diabetes mellitus



PubMed 的索引名詞 - MeSH名詞



	語法	功能
MeSH名詞	【MeSH】	搜尋標有該MeSH名詞的文章
MeSH名詞主題	【Mejr】	搜尋以該MeSH名詞為主題的文章

- PubMed已經可以同時以自然語言及MeSH進行搜尋
- 要限定只搜尋特定MeSH名詞，可鍵入” “drug utilization evaluation”【 MeSH 】

My NCBI 個人化服務

- 點選右上角之”My NCBI”
- 登入個人帳號密碼



MyNCBI 個人化服務



編輯filters


NCBI
Resources
How To
My NCBI — Filters
You are managing filters for: PubMed
Choose another database:
PubMed (11 active)
Your PubMed filter list
Create custom filter
Active
Name
Type
Therapy
Custom
delete
Diagnosis
Custom
delete
Economics
Custom
delete
Systematic Review
Custom
delete
Clinical Trial
Standard filter
Meta-analysis
Standard filter
Practice Guideline
Standard filter
Published in the last 5 years
Standard filter
Randomized Controlled Trial
Standard filter
Review
Standard filter
Therapy/Broad
Browse/Search for PubMed Filters
Select category:
Popular
LinkOut
Properties
Links
Search with terms (optional):
Search
Active
Name
Description
Clinical Trial
English
English & Humans
Free Full Text
links to Web accessible full text articles (all ava
free of charge)
Full Text
links to Web accessible full text articles (some
require subscription)
tracts
我個人設定好的filters

Filter分類篩選設定



((clinical[Title/Abstract] AND trial[Title/Abstract]) OR clinical trials[MeSH Terms] OR clinical trial[Publication Type] OR random*[Title/Abstract] OR random allocation[MeSH Terms] OR therapeutic use[MeSH Subheading])

臨床文獻最佳化篩選介面
Clinical Queries



Clinical Study Categories -Research Methodology Filters

Filter info

Clinical Queries using Research Methodology Filters

Category	Optimized For	Sensitive/ Specific	PubMed Equivalent
therapy	sensitive/broad	99%/70%	((clinical[Title/Abstract] AND trial[Title/Abstract]) OR clinical trials[MeSH Terms] OR clinical trial[Publication Type] OR random*[Title/Abstract] OR random allocation[MeSH Terms] OR therapeutic use[MeSH Subheading])
	specific/narrow	93%/97%	(randomized controlled trial[Publication Type] OR (randomized[Title/Abstract] AND controlled[Title/Abstract] AND trial[Title/Abstract]))
diagnosis	sensitive/broad	98%/74%	(sensitiv*[Title/Abstract] OR sensitivity and specificity[MeSH Terms] OR diagnos* [Title/Abstract] OR diagnosis[MeSH:noexp] OR diagnostic * [MeSH:noexp] OR diagnosis,differential[MeSH:noexp] OR diagnosis[Subheading:noexp])
	specific/narrow	64%/98%	(specificity[Title/Abstract])
etiology	sensitive/broad	93%/63%	(risk*[Title/Abstract] OR risk*[MeSH:noexp] OR risk *[MeSH:noexp] OR cohort studies [MeSH Terms] OR group*[Text Word])
	specific/narrow	51%/95%	((relative[Title/Abstract] AND risk*[Title/Abstract]) OR (relative risk[Text Word]) OR risks[Text Word] OR cohort studies[MeSH:noexp] OR (cohort[Title/Abstract] AND stud*[Title/Abstract]))
prognosis	sensitive/broad	90%/80%	(incidence[MeSH:noexp] OR mortality[MeSH Terms] OR follow up studies [MeSH:noexp] OR prognos*[Text Word] OR predict*[Text Word] OR course*[Text Word])
	specific/narrow	52%/94%	(prognos*[Title/Abstract] OR (first[Title/Abstract] AND episode[Title/Abstract]) OR cohort[Title/Abstract])
clinical prediction guides	sensitive/broad	96%/79%	(predict*[tiab] OR predictive value of tests[mh] OR scor*[tiab] OR observ*[tiab] OR observer variation[mh])
	specific/narrow	54%/99%	(validation[tiab] OR validate[tiab])

Filter分類篩選設定



((clinical[Title/Abstract] AND trial[Title/Abstract]) OR clinical trials[MeSH Terms] OR clinical trial[Publication Type] OR random*[Title/Abstract] OR random allocation[MeSH Terms] OR therapeutic use[MeSH Subheading])

You are managing filters for: PubMed

Your PubMed filter list

Create custom filter

Active	Name	Type	
☑	Therapy	Custom	delete
☑	Diagnosis	Custom	delete
☑	Economics	Custom	delete
☑	Systematic Review	Custom	delete
☑	Clinical Queries-therapy narrow	Custom	delete
☑	Clinical Trial	Standard filter	
☑	Meta-analysis	Standard filter	
☑	Practice Guideline	Standard filter	
☑	Published in the last 5 years	Standard filter	
☑	Randomized Controlled Trial	Standard filter	
☑	Review	Standard filter	
☑	Therapy/Broad	Standard filter	


NCBI Resources How To
ed100645 My NCBI Sign Out
PubMed.gov
US National Library of Medicine
National Institutes of Health
PubMed
Dronedarone
RSS Save search Advanced
Help
Choose additional filters
Text availability
Abstract available
Free full text available
Full text available
Publication dates
5 years
10 years
Custom range...
Species
Humans
Other Animals
Article types
Clinical Trial
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
Systematic Reviews
more ...
Languages
English
more ...
Display Settings: Summary, 20 per page, Sorted by Recently Added
Results: 1 to 20 of 352
<< First < Prev
1. Efficacy and safety profile of dronedarone in clinical practice. Results of
Registry (MADRE study).
Said SM, Esperer HD, Kluba K, Genz C, Wiedemann AK, Boenigk H, Herc
Dullaeus RC.
Int J Cardiol. 2012 Jul 9. [Epub ahead of print]
PMID: 22781508 [PubMed - as supplied by publisher]
Related citations
2. Cost-Effectiveness of Dronedarone in Atrial Fibrillation: Results for Cana
Switzerland.
Akerborg O, Nilsson J, Bascle S, Lindgren P, Reynolds M.
Clin Ther. 2012 Jul 5. [Epub ahead of print]
PMID: 22770643 [PubMed - as supplied by publisher]
Related citations
3. Proarrhythmic Potential of Dronedarone: Emerging Evidence from Spont
Reporting.
Kao DP, Hiatt WR, Krantz MJ.
Pharmacotherapy. 2012 Jun 28. doi: 10.1002/j.1875-9114.2012.01118.x. [Epub ahead
PMID: 22744806 [PubMed - as supplied by publisher]
Related citations
4. Addressing the management of atrial fibrillation - a systematic review of the role of dronedarone.
Filter your results:
All (352)
Clinical Trial (19)
Practice Guideline (3)
Published in the last 5 years (272)
Randomized Controlled Trial (17)
Review (126)
Therapy/Broad (275)
Therapy (273)
Diagnosis (144)
Economics (7)
Systematic Review (129)
Clinical Queries-therapy narrow (23)
dronedarone in high risk permanent atrial fibrillation


My NCBI
Customize this page | NCBI Site Preferences | Video | view | Help
Search NCBI databases
Search : PubMed
Search
Hint: clicking the "Search" button without any terms listed in the search box will transport you to that database's homepage.
Saved Searches
Search Name
earched
PubMed Searches
((oligospermia OR male infertility OR (Male [MeS...
6
2 months ago
喜好設定
Common Preferences
Username
ed100645
Password
******
E-mail Address
melody_0320@hotmail.com (confirmed)
Links Display
Popup Menu
Highlighting
Yellow
Shared Settings
None
Linked Account
None
關鍵字以顏色標
PubMed Preferences
Abstract Supplemental Data
Closed
Document Delivery
None Selected
PubMed Filters & Icons
Clinical Trial, Practice Guideline, Published in the l
Therapy, Diagnosis, Economics, Systematic Revie
Outside Tool
None Selected
Auto Suggest
On
Result Display Settings
Summary, 20, Recently Added
Many of NCBI's databases can use color to highlight the sea
None
Bold
Light Yellow
Green
Purple
Aqua
Gold
Yellow
Sky Blue
Lime Green
Hot Pink
Red
Save
Or cancel and return to the preferences page

藥物資訊查詢
_替代藥品

病患罹患心律不整又合併心衰竭時，該如何選擇?

MICROMEDEX® 2.0

UpToDate ONLINE

UpToDate ONLINE

關鍵字

antiarrhythmic, heart failure



Atrial fibrillation in patients with heart failure

基本藥物資訊查詢
_交互作用

Tamoxifen與Warfarin是否可以併用?

遇到交互作用問題，該怎麼做呢?

- 衛生署藥品交互作用資料庫 (關閉中)
- **Drug Interaction Facts**
- MICROMEDEX® 2.0



院內交互作用查詢系統

一、依藥品組合查詢：

步驟1. 請拉選查詢藥品: Tamoxifen 10mg/tab (學名)

步驟2. 請拉選比對藥品: ---- (學名) 開始查詢

*若選擇All則對所有藥品進行比對

步驟3. 查詢結果:6筆

二、依查詢藥品名稱字首查詢：A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

查詢藥品名稱	比對藥品名稱	影響等級	Onset	Severity	Documentation	Effects	
Tamoxifen 10mg/tab	Rifabutin 150mg/cap	2	Delayed	Moderate	Suspected	TAMOXIFEN plasma concentrations may be reduced, decreasing the antiestrogenic effect.	Monitor the c TAMOXIFEN
Tamoxifen 10mg/tab	Rifampin 150mg+Isoniazide 100mg (Rifinah)	2	Delayed	Moderate	Suspected	TAMOXIFEN plasma concentrations may be reduced, decreasing the antiestrogenic effect.	Monitor the c TAMOXIFEN
Tamoxifen 10mg/tab	Rifampin 150mg/cap	2	Delayed	Moderate	Suspected	TAMOXIFEN plasma concentrations may be reduced, decreasing the antiestrogenic effect.	Monitor the c TAMOXIFEN
Tamoxifen 10mg/tab	Rifampin 300mg + Isoniazide 150mg (Rifinah)	2	Delayed	Moderate	Suspected	TAMOXIFEN plasma concentrations may be reduced, decreasing the antiestrogenic effect.	Monitor the c TAMOXIFEN
Tamoxifen 10mg/tab	Rifampin(RIF) 300mg/cap	2	Delayed	Moderate	Suspected	TAMOXIFEN plasma concentrations may be reduced, decreasing the antiestrogenic effect.	Monitor the c TAMOXIFEN
Tamoxifen 10mg/tab	Rifampin+INAH+PZA(Rifater)	2	Delayed	Moderate	Suspected	TAMOXIFEN plasma concentrations may be reduced, decreasing the antiestrogenic effect.	Monitor the c TAMOXIFEN

- Tamoxifen與Warfarin併用安全嗎?

Drug Interaction Facts



David S. Tatro, PharmD

Drug Interaction Facts™

THE AUTHORITY ON DRUG INTERACTIONS

2012

Wolters Kluwer Health | Facts & Comparisons®

182

Anticoagulants — **Tamoxifen**

Warfarin* (eg, Coumadin) — Tamoxifen*

Warfarin

Significance	Onset	Severity	Documentation
1	☐ Rapid ■ Delayed	■ Major ☐ Moderate ☐ Minor	☐ Established ☐ Probable ■ Suspected ☐ Possible ☐ Unlikely

延遲　嚴重　可疑

Effects — The hypoprothrombinemic effect of oral ANTICOAGULANTS may be increased, possibly with bleeding.

Mechanism — Unknown.

Management — If an interaction is suspected, consider decreasing the dose of oral ANTICOAGULANTS during coadministration of TAMOXIFEN. Monitor PT and adjust the dose accordingly.

2 Venlafaxine, 1772

4 Warfarin, 182

~~Tamsulosin,~~

2 Ethanol, 40

2 Tadalafil, 43

2 Vardenafil, 1979

勘誤!!


MICROMEDEX® 2.0 | 移動
我的訂閱 | MICROMEDEX 閘道 | 登出
工具:
藥物 相互作用
1
Trissel's™2 IV 相容性
藥物 鑒定
Tox 和藥物 產品查找
藥物 比較
計算器
CareNotes®
藥物相互作用
在搜尋欄位鍵入藥物名稱（品牌或學名藥）。選擇藥物並按一下 （新增）按鈕。
輸入搜尋詞:
2
相符的藥物名稱: (3)
Warfarin
Warfarin Sod
Warfarin Sodium
要檢查的藥物：
Add Allergies
Tamoxifen Citrate
Warfarin
帶有星號 (*) 的字母大寫項目表示過敏 -
3
清除
提交

列印

Drug Interaction Results

修改相互作用

組化方式： 藥物： All 嚴重性： All 文件： All 類型： All

跳轉到： 藥物 -藥物 (1) | 複方 (0) | 過敏症狀 (0) | 食物 (6) | 乙醇 (1) | 實驗室 (0) | 抽煙 (1) | 懷孕 (2) | 哺乳期 (2)

Drug-Drug 相互作用 (1)

藥物：	嚴重性：	文件：	綜述：
TAMOXIFEN CITRATE [Systemic] -- WARFARIN SODIUM [Systemic] [Warfarin]	Contraindicated	Good	Concurrent use of TAMOXIFEN and WARFARIN may result in an increased risk of bleeding.

強烈建議相互作用的存在

複方 （未找到）

Drug-過敏症狀 相互作用 （未找到）

Drug-食物 相互作用 (6)

藥物：	嚴重性：	文件：	綜述：
WARFARIN SODIUM [Systemic] [Warfarin]	Major	Good	Concurrent use of WARFARIN and POMEGRANATE may result in increased warfarin plasma concentrations and increased risk of bleeding.
WARFARIN SODIUM [Systemic] [Warfarin]	Major	Good	Concurrent use of WARFARIN and CRANBERRY JUICE may result in an increased risk of bleeding.

2012年7

Drug Interaction Results 修改相互作用

細化方式： 藥物： All

跳轉到： 藥物 -藥物 (

Drug-Drug 相互作用

藥物：

TAMOXIFEN CITRATE [S
[Systemic] [Warfarin]

複方（未找到）

Drug-過敏症狀 相互

Drug-食物 相互作用

藥物：

WARFARIN SODIUM [Sy

WARFARIN SODIUM [Systemic] [Warfarin] Major Good Concurrent use of WARFARIN and CRAN

(2)

d WAR

POME

a conc

INTERACTION DETAIL

Warning:

可能增加病患出血的風險

Concurrent use of TAMOXIFEN and WARFARIN may result in an increased risk of bleeding.

Clinical Management:

Concurrent administration of tamoxifen and coumarin-type anticoagulants, including warfarin, is contraindicated in high-risk women and women with ductal carcinoma in situ where tamoxifen is used to reduce the incidence of breast cancer. In other clinical situations where tamoxifen is used concurrently with warfarin, consider using lower warfarin doses and closely monitor the INR (international normalized ratio) with the addition and withdrawal of treatment with tamoxifen and periodically.

Onset:

Delayed

Severity:

Contraindicated

Documentation:

1.考慮使用較低的劑量
2.密切監測INR值

列印 關閉

查詢多重藥品交互作用...


藥物相互作用
在搜尋欄位鍵入藥物名稱（品牌或學名藥）。選擇藥物並按一下 （新增）按鈕。
輸入搜尋詞:
可鍵入多種藥品一併作完整的比對
相符的藥物名稱: (3)
Warfarin
Warfarin Sod
Warfarin Sodium
要檢查的藥物：
Add Allergies
Losartan Potassium
Metformin Hydrochloride
Tamoxifen Citrate
Warfarin
帶有星號 (*) 的字母大寫項目表示過敏。
清除
提交

Drug Interaction Results

修改相互作用

細化方式： 藥物： All 嚴重性： All 文件： All 類型： All

跳轉到： 藥物 -藥物 (1) | 複方 (0) | 過敏症狀 (0) | 食物 (7) | 乙醇 (2) | 實驗室 (0) | 抽煙 (1) | 懷孕 (4) | 哺乳期 (4)

Drug-過敏症狀 相互作用 （未找到）

Drug-食物 相互作用 (7)

藥物：	嚴重性：	文件：	綜述：
WARFARIN SODIUM [Systemic] [Warfarin]	S Major	Good	Concurrent use of WARFARIN and POMEGRANATE may result in increased warfarin plasma concentrations and increased risk of bleeding.
WARFARIN SODIUM [Systemic] [Warfarin]	S Major	Good	Concurrent use of WARFARIN and CRANBERRY JUICE may result in an increased risk of bleeding.
WARFARIN SODIUM [Oral (systemic)] [Warfarin]	! Moderate	Good	Concurrent use of WARFARIN and ENTERAL NUTRITION may result in decreased PT/INR response to warfarin and development of warfarin resistance.
WARFARIN SODIUM [Systemic] [Warfarin]	! Moderate	Good	Concurrent use of WARFARIN and NONI JUICE may result in risk of acquiring warfarin resistance.
WARFARIN SODIUM [Systemic] [Warfarin]	! Moderate	Good	Concurrent use of WARFARIN and HIGH-PROTEIN DIET may result in reduced warfarin anticoagulant effectiveness.
WARFARIN SODIUM [Systemic] [Warfarin]	! Moderate	Excellent	Concurrent use of WARFARIN and VITAMIN K FOODS may result in altered anticoagulant effectiveness.
LOSARTAN POTASSIUM [Systemic]	M Minor	Good	Concurrent use of LOSARTAN and GRAPEFRUIT JUICE may result in increased half-life (t1/2) and decreased area under the concentration time curve (AUC) of losartan's active metabolite (E3174).

MICROMEDEX® 2.0

- Mobile website: all devices
- Comprehensive drug information
- Access at the bedside (point of care)
- NO FEE



Medical App: Micromedex Drug Information



Medical App: Micromedex Drug Information





展開後的內容

Thank you!


Invitation
2012台灣臨床藥學年會
時間：2012.11.04 星期日
地點：高雄義大皇冠假日飯店
CROWNE PLAZA
社團法人台灣臨床藥學會
誠摯邀請您